<DOC>
	<DOCNO>NCT00814489</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity 2 formulation non-typable Haemophilus influenzae pneumococcal candidate vaccine young adult . Subjects vaccinate 2 time observer-blind manner interval 2 month . The subject receive Engerix-B receive open-manner third dose vaccine Month 6 . The protocol post update follow protocol amendment .</brief_summary>
	<brief_title>Evaluation Non-typable Haemophilus Influenzae Pneumococcal Protein Vaccine Formulations Young Adults</brief_title>
	<detailed_description>This Protocol Posting update follow amendment Protocol , January 2010 . The section impact : study design study endpoint .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 40 year age time first vaccination . Written inform consent obtain subject . Subject without medical history , clinical find laboratory finding , , opinion investigator , could pose safety concern interfere protocol . If subject female , childbearing potential , agree use adequate contraception become pregnant duration study . Pneumonia within 3 year prior 1st vaccination . Invasive Pneumococcal Disease within 3 year prior 1st vaccination . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day first dose vaccine , exception influenza vaccine administer &gt; 14 day prior &gt; 14 day follow vaccine dose 1 2 . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . History reaction hypersensitivity component vaccine . Any serious , uncontrolled disease likely interfere study determine history , physical examination laboratory screening , per judgment Investigator . Inflammatory process know chronic infection . All past current malignancy lymphoproliferative disorder . Laboratory evidence haematological biochemical abnormality . Acute disease time enrolment/vaccination . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Other condition principal investigator judge may interfere study finding . Previous vaccination hepatitis B . As portion subject randomize receive EngerixB comparator , important subject meet EngerixB eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Non-typable Haemophilus influenzae</keyword>
	<keyword>protein vaccine</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>young adult</keyword>
</DOC>